211 related articles for article (PubMed ID: 26838196)
1. Factors Predicting Early Release of Thyroid Cancer Patients from the Isolation Room after Radioiodine-131 Treatment.
Fatima N; Zaman Mu; Zaman A; Zaman U; Tahseen R; Shahid W
Asian Pac J Cancer Prev; 2016; 17(1):125-9. PubMed ID: 26838196
[TBL] [Abstract][Full Text] [Related]
2. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
4. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
[TBL] [Abstract][Full Text] [Related]
5. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
6. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
7. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
8. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
9. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
10. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
[TBL] [Abstract][Full Text] [Related]
11. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
[TBL] [Abstract][Full Text] [Related]
12. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
13. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
14. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
[TBL] [Abstract][Full Text] [Related]
16. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
17. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
20. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
